News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingKey Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
INmune Bio Inc. announced its second-quarter 2026 financial results, highlighting significant progress in its regulatory filings, manufacturing capabilities, and ongoing clinical trials. The company is advancing its pipeline with key developments in its drug candidates, reflecting a productive period for research and development. This …
INmune Bio Inc. (INMB) reported a net loss of $6.7 million for the six months ended June 30, 2026, a significant improvement from the previous year's $34.2 million loss, primarily due to reduced Alzheimer's program spending and the absence of a prior impairment charge. …
INmune Bio Inc. (INMB) is a biotechnology company focused on developing therapies for immune-related diseases and cancer. The article provides its current stock price, recent financial performance, and a series of news and press releases highlighting progress in its clinical trials for Alzheimer's disease …
Inmune Bio, Inc. reported its Q2 2026 results, showing no revenue but a significant improvement in net loss to $(1.27)M from $(24.46)M in the prior year, with diluted EPS improving to $(0.05). The company highlighted progress in its lead program CORDStrom, with plans for …
INmune Bio reported $0 revenue and a narrowed net loss of $1.3 million in Q2 2026, primarily due to an Australian R&D tax rebate and the absence of a prior-year impairment. The company advanced its pipeline with Ebstrocel moving closer to regulatory filings in …
INmune Bio (INMB.US) is scheduled to release its earnings report after the market closes on August 6. Investors will be awaiting this report for insights into the company's financial performance.
This article provides recent news and financial updates concerning INmune Bio Inc. (NASDAQ: INMB), including earnings transcripts, stock movements, and analyst reports. Key events include Q4 2025 and Q1 2026 earnings, discussions around its Alzheimer's drug trial, and significant stock fluctuations. The company's stock …
INmune Bio Inc. announced it received a $4.2 million R&D cash rebate from Australia and an additional $0.4 million from the UK, significantly enhancing its financial position. These non-dilutive funds exceed the company's net cash usage for the second quarter and extend its cash …
INmune Bio Inc. announced it has received approximately $4.6 million in research and development cash rebates from government programs in Australia and the United Kingdom. These rebates, which include $4.2 million from Australia and $0.4 million from the UK, exceeded the company’s net cash …
INmune Bio (NASDAQ: INMB) announced it will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. Eastern Time, to discuss its second-quarter 2026 financial results and provide a corporate update. The company will also detail advancements in its CORDStrom …
INmune Bio Inc. announced it will host a conference call on Thursday, August 6th, 2026, at 4:30 p.m. EDT to discuss its second-quarter financial results for the period ended June 30, 2026, and to provide a corporate update. The company, a late-stage biotechnology firm, …
INmune Bio, Inc. has formed a Scientific Advisory Board (SAB) to guide the late-stage development of Ebstrocel™ for recessive dystrophic epidermolysis bullosa (RDEB) and to expand its CORDStrom™ mesenchymal stromal cell (MSC) platform to new disease indications. The SAB, chaired by Professor Mark Lowdell, …
This article provides a financial health analysis of INmune Bio Inc (INMB), noting its current financial score of 7.63, ranking it 97th in the Biotechnology & Medical Research industry. Despite a robust financial status, the company shows low operating efficiency, with recent quarterly revenue …
This article provides a detailed financial overview of INmune Bio Inc (INMB), including its stock price, market cap, and key financial indicators. It presents extensive quarterly and annual data for income statements, balance sheets, and cash flow statements. The report also highlights the latest …
The article provides dividend and stock split information for INmune Bio Inc (INMB). It states that no dividends have been distributed over the past five years. The page displays current stock metrics including price, market cap, and links to other company financial data.
INmune Bio (INMB) has seen its target fair value raised to $7.00 due to updated analyst assumptions concerning revenue growth, profit margin, and P/E multiple. The company has made significant progress in its cell therapy platform, including processing its first commercial-ready umbilical cord tissue …
INmune Bio Inc (INMB) has an institutional shareholding score of 3.00, placing it 192nd out of 386 in its industry. The institutional shareholding proportion has increased by 8.44% quarter-over-quarter to 18.84%. BlackRock Institutional Trust Company and State Street Investment Management are among the top …
This article provides a risk assessment for INmune Bio Inc (INMB), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 2.99, ranking 167 out of 386 in the Biotechnology & Medical Research industry, with a beta of …
This article provides a technical analysis of INmune Bio Inc (INMB), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The stock is currently trading between a resistance level of 2.05 and a support …
Inmune Bio (INMB) is a clinical-stage biotech company listed on Nasdaq, focused on neuroinflammation and oncology. The company reported $50 million in cash and equivalents as of Q1 2026, with an increasing net loss of $12 million for the quarter, largely driven by expanded …
INmune Bio announced the completion of a significant commercial manufacturing milestone for its CORDStrom™ platform, successfully processing the first commercial-ready umbilical cord tissue. This achievement allows for the creation of US-tested master cell banks for Ebstrocel™, supporting planned Phase 3 trials and future commercial …
This article highlights three promising penny stocks: INmune Bio (INMB), Identiv (INVE), and Vera Bradley (VRA). Each company is pre-revenue or unprofitable but shows financial resilience, no significant debt, and potential for future growth through strategic advancements or partnerships. The analysis provides financial health …
INmune Bio Inc. has reached a significant manufacturing milestone for its CORDStrom™ platform, successfully processing the first commercial-ready umbilical cord tissue under global regulatory standards. This achievement allows the company to create master cell banks for its investigational product, Ebstrocel™, aimed at recessive dystrophic …
INmune Bio announced the completion of a commercial manufacturing milestone for its CORDStrom platform, which supports planned global registration filings. The first commercial-ready umbilical cord tissue was processed in the UK, paving the way for a planned Phase 3 trial for Ebstrocel in RDEB, …
INmune Bio Inc. announced the publication of a preclinical study in the Journal of Neurotrauma, revealing a link between traumatic brain injury and Alzheimer's disease. The study, funded by the Department of Defense, found that a single brain injury increased levels of Alzheimer's-associated proteins, …
INmune Bio announced a peer-reviewed preclinical study demonstrating that its drug XPro1595 can prevent TBI-driven amyloid pathology and cognitive decline in an Alzheimer's model by inhibiting soluble TNF. This research suggests a crucial link between traumatic brain injury and Alzheimer's disease through soluble TNF-driven …
INmune Bio announced a preclinical study published in the Journal of Neurotrauma indicating that its drug candidate, XPro1595, prevents Alzheimer's pathology, memory loss, and pain induced by traumatic brain injury (TBI). The study found that XPro1595 neutralizes soluble TNF, a key inflammatory cytokine linking …
Search by ticker symbol or company name and select a result to open its chart.